Disease · MONDO_0003004

macular degeneration

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. macular degeneration. Diseases, record MONDO_0003004. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003004

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: macular degeneration; Open Targets
Open Targets ID: MONDO_0003004; Open Targets
Other names: macula lutea retinal degeneration, macula retinal degeneration, retinal degeneration of macula lutea; Open Targets
Disease Ontology: DOID:4448; Disease Ontology
MeSH: D008268; MeSH
NCI Thesaurus: C123330; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 25 drugs, from EMA Human Drugs, PMDA and TTD; Open Targets

Drugs25

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	PMDA	3	2	2	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Approval	PMDA	3	2	2	Drugs and targets
ANECORTAVE ACETATE	CHEMBL2106613	Small molecule	Approval	TTD	1	0	0	Drugs and targets
BROLUCIZUMAB	CHEMBL3707357	Antibody	Approval	PMDA	1	0	0	Drugs and targets
PEGAPTANIB SODIUM	CHEMBL1201421	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VERTEPORFIN	CHEMBL5314346	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
AVACINCAPTAD PEGOL	CHEMBL6068573	Oligonucleotide	Phase 3	TTD	2	0	0	Drugs and targets
FENRETINIDE	CHEMBL7301	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
ABICIPAR PEGOL	CHEMBL4297684	Protein	Phase 2	TTD	2	0	0	Drugs and targets
AL-78898A	CHEMBL4594457		Phase 2	TTD	1	0	0	Drugs and targets

1 to 10 of 25

See all 25 drugs

Targets27

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	Vascular endothelial growth factor A, long form	5	Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
C3	Complement C3	2	Complement C3 inhibitor	Phase 2	https://conductscience.org/library/genes/718	Drugs and targets
C5	Complement C5	2	Complement C5 binding agent; Complement C5 inhibitor	Phase 2	https://conductscience.org/library/genes/727	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
BLK	SRC	1	SRC inhibitor	Phase 2	https://conductscience.org/library/genes/640	Drugs and targets
CXCL12	Stromal cell-derived factor 1	1	Stromal cell-derived factor 1 inhibitor	Phase 1	https://conductscience.org/library/genes/6387	Drugs and targets
CXCR4	C-X-C chemokine receptor type 4	1	C-X-C chemokine receptor type 4 antagonist	Phase 2	https://conductscience.org/library/genes/7852	Drugs and targets
ENG	Endoglin	1	Endoglin inhibitor	Phase 2	https://conductscience.org/library/genes/2022	Drugs and targets

1 to 10 of 27

See all 27 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00896779	Lucentis in Advanced Macular Degeneration	Phase 2	20	2015-05-27	Macular Degeneration	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02067013	Analysis of Aqueous and Vitreous Humor	Phase 2	45		Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06132035	Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration	Phase 1	45		Age-related Wet Macular Degeneration	AFLIBERCEPT	Open Targets' reading of its record	ClinicalTrials.gov
NCT01495208	Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment	Phase 4	0		Fibrovascular Pigment Epithelial Detachment	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Ranibizumab Group 1 vs Ranibizumab Group 2: serious adverse events	0 of 8	0 of 12	20	NCT00896779

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003004

GET https://conductscience.org/api/diseases/v1/MONDO_0003004/drugs?page=2

API reference For AI assistants